by mpzzqmvj | Jun 14, 2021 | Press Releases
GAINESVILLE, Fla. – Cyclo Therapeutics, Inc. (Nasdaq: CYTH) (“Cyclo Therapeutics” or the “Company”), a clinical stage biotechnology company dedicated to developing life-changing medicines through science and innovation for patients and...
by mpzzqmvj | Jun 9, 2021 | Press Releases
Live video webcast presentation with members of the Company’s executive leadership team on Thursday, June 17th at 12:30 PM ETGAINESVILLE, Fla. – Cyclo Therapeutics, Inc. (Nasdaq: CYTH) (“Cyclo Therapeutics” or the “Company”), a...
by mpzzqmvj | May 20, 2021 | Press Releases
– Panel discussion around innovating Alzheimer’s Disease (“AD”) drug development on Wednesday, May 26th 11:00 AM ETGAINESVILLE, Fla. – Cyclo Therapeutics, Inc. (Nasdaq: CYTH) (“Cyclo Therapeutics” or the...
by mpzzqmvj | May 17, 2021 | Press Releases
– Pivotal Phase 3 study of Trappsol® Cyclo™ for Niemann-Pick Disease Type C (NPC) on track to commence enrollment and dosing in Q2 2021- Company advancing Alzheimer’s Disease Phase 2 asset towards investigational new drug application (IND)...
by mpzzqmvj | May 11, 2021 | Press Releases
Ms. Gorski brings more than two decades of communications and patient advocacy experience serving rare disease communitiesFormerly led global communications and patient advocacy strategies for lysosomal storage disorders at Sanofi Genzyme GAINESVILLE, Fla. –...
by mpzzqmvj | Apr 27, 2021 | Press Releases
Patient enrollment on track to commence in Q2 2021Global clinical protocol agreed with US Food and Drug Administration (FDA) and European MedicinesAgency (EMA)Dual primary objectives agreed; FDA 4-Domain Niemann-Pick disease Type C-Severity Scale (4D-NPC-SS) and EMA...
